All AbMole products are for research use only, cannot be used for human consumption.
Mirvetuximab soravtansine is an antibody-drug concatenation (ADC) containing a folate receptor alpha (frα)-conjugated antibody, a cleavable junction, and the medenosine alkaloid DM4, a potent microtubulin-targeting agent, that can be used in studies related to platinum-resistant epithelial ovarian cancer (EOC).
| Molecular Weight | 977.59 |
| Formula | C42H61ClN4O14S3 |
| CAS Number | 1453084-37-1 |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[1] Young-A Heo. Drugs. Mirvetuximab Soravtansine: First Approval
| Related ADC Linker Products |
|---|
| 6-Maleimidohexanoic acid N-hydroxysuccinimide ester
6-Maleimidohexanoic acid N-hydroxysuccinimide ester(ECMS) is a useful protective group in antibody drug conjugates. |
| Sulfo-NHS
Sulfo-NHS is a peptide condensing agent, can form a stable active ester intermediate, used to prepare hydrophilic active ester, for example as a protein cross-linking agent. N-Hydroxysulfosuccinimide (sodium) is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). |
| SPDP Crosslinker
SPDP crosslinker, or SPDP NHS ester, is a cleavable, water insoluble, amino and thiol (sulfhydryl) reactive heterobifunctional protein crosslinker. *The compound is unstable in solutions, freshly prepared is recommended |
| Mc-Val-Cit-PAB
Mc-Val-Cit-PAB is a peptide linker molecule used in the synthesis of antibody-drug conjugates (ADCs). |
| Fmoc-Val-Cit-PAB
Fmoc-Val-Cit-PAB-OH is a cleavable useful heterobifunational linker for making Antibody-Drug-Conjugates (ADC). |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
